Inventor · disambiguated record

Chih-Chiang Tsou

Also filed as: TSOU CHIH-CHIANG

74 granted patents·18 pending applications·15 citations·filing 2019–2024

99Inventor score

Technology areasA61K C07K G01N

Files withIMMATICS BIOTECHNOLOGIES GMBH91 IMMATICS US INC1

Top patents by PatentIndex Score

92 records

0198US10772915B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 15, 2020·5 cites·20 claims
0298US10695374B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·5 cites·26 claims
0397US10709738B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 14, 2020·3 cites·20 claims
0495US11020433B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 1, 2021·2 cites·20 claims
0591US12318407B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Jun 3, 2025·0 cites·20 claims
0691US12290530B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted May 6, 2025·0 cites·20 claims
0791US12285443B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 29, 2025·0 cites·20 claims
0891US12274716B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 15, 2025·0 cites·20 claims
0991US12257269B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 25, 2025·0 cites·20 claims
1091US12246039B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 11, 2025·0 cites·20 claims
1191US2023285461A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1291US2023285462A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1390US2023241109A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1490US2024307447A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1590US2023241112A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1690US2023241113A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1790US2024269183A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1890US2024374642A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1990US2024358757A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2090US2023285460A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2190US2023241110A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2290US2023233612A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2390US2023241108A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2490US2023241114A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2590US2023241115A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2690US2023263830A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2789US10709736B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 14, 2020·0 cites·35 claims
2889US10702553B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 7, 2020·0 cites·25 claims
2989US10695376B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·25 claims
3089US10695377B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·27 claims
3189US10695375B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·22 claims
3288US10695373B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·25 claims
3386US11077142B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Aug 3, 2021·0 cites·20 claims
3486US11033583B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·20 claims
3586US10993962B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 4, 2021·0 cites·12 claims
3686US10894064B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 19, 2021·0 cites·20 claims
3785US11369636B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 28, 2022·0 cites·20 claims
3885US11357797B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 14, 2022·0 cites·20 claims
3984US11951132B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Apr 9, 2024·0 cites·20 claims
4084US11918607B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 5, 2024·0 cites·20 claims
4184US11376281B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 5, 2022·0 cites·20 claims
4283US11197892B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 14, 2021·0 cites·20 claims
4383US11179418B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 23, 2021·0 cites·20 claims
4482US11957716B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Apr 16, 2024·0 cites·27 claims
4582US11801264B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 31, 2023·0 cites·20 claims
4682US11779606B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 10, 2023·0 cites·20 claims
4782US11154576B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 26, 2021·0 cites·20 claims
4882US11147839B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 19, 2021·0 cites·20 claims
4982US11147838B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 19, 2021·0 cites·20 claims
5082US11141437B2Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 12, 2021·0 cites·20 claims

Showing the top 50 of 92 patent records by PatentIndex Score.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →